-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cervical cancer is the second most common malignancy in women aged 15-44
The research team carried out a multi-center, randomized, double-blind, controlled (hepatitis E vaccine Yikening ? ) Phase III clinical trial of Xinkening ? based on 5 sites across the country.
The results of the final analysis of the 66-month follow-up of the Phase III clinical trial of Cincogene® showed that in the per-protocol set (PPS) population, the vaccine was effective against HPV type 16 and/or 18 infection-related lesion endpoints (CIN2+ and/or or VIN2+ and/or VaIN2+) protection was 100.
Recently, the research results are titled "Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Human Papillomavirus (types 16 and 18) L1 Virus-like-particle Vaccine: end-of-study analysis of a phase 3 double-blind, The randomized controlled trial" paper is published online in The Lancet Infectious Diseases
Paper link:National Research Center for Infectious Disease Diagnostic Reagents and Vaccine Engineering Technology)